Sensei Biotherapeutics Inc

+0.02 (+1.45%)
Earnings Announcements

Sensei Biotherapeutics Reports Q3 Results

Published: 11/08/2022 13:01 GMT
Sensei Biotherapeutics Inc (SNSE) - Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights.
Qtrly Loss per Share $0.44.
Cash, Cash Equivalents and Marketable Securities Were $116.6 Million As of September 30.
Ns-101 Preclinical Data Demonstrate a Favorable Pharmacokinetic Profile.
Sns-101 Preclinical Data Demonstrate Evidence of Advanced Anti-tumor Effects and a Superior Cytokine Release Profile.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.41

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.41

More details on our Analysts Page.